Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.

Factors that aid survival of prostate cancer cells in the presence of the various categories of cytotoxic cytokines present in tumors in vivo are largely unknown. Osteoprotegerin (OPG) is a decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) that inhibits TRAIL-induced...

תיאור מלא

מידע ביבליוגרפי
Main Authors:	Holen, I, Croucher, P, Hamdy, F, Eaton, C
פורמט:	Journal article
שפה:	English
יצא לאור:	2002

פריטים דומים

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
מאת: Eaton, C, et al.
יצא לאור: (2004)

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
מאת: Eaton, C, et al.
יצא לאור: (2004)

OPG is a survival factor for breast- and prostate cancer cells in vitro
מאת: Holen, I, et al.
יצא לאור: (2002)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
מאת: Holen, I, et al.
יצא לאור: (2002)

Role of osteoprotegerin (OPG) in cancer.
מאת: Holen, I, et al.
יצא לאור: (2006)

The role of osteoprotegerin in breast and prostate cancer
מאת: Holen, I, et al.
יצא לאור: (2002)

Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact
מאת: Holen Ingunn, et al.
יצא לאור: (2009-07-01)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
מאת: Shipman, C, et al.
יצא לאור: (2002)

Role of Osteoprotegerin (OPG) in Bone Marrow Adipogenesis
מאת: Lili Zhang, et al.
יצא לאור: (2016-11-01)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
מאת: Shipman, C, et al.
יצא לאור: (2002)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
מאת: Shipman, C, et al.
יצא לאור: (2000)

Serum osteoprotegerin (OPG) in children with primary nephrotic syndrome
מאת: Gamal B Mohamed, et al.
יצא לאור: (2011-01-01)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
מאת: Waterman, E, et al.
יצא לאור: (2007)

Polymorphisms within the osteoprotegerin (OPG) gene are associated with both serum OPG levels and bone mineral density.
מאת: Miles, L, et al.
יצא לאור: (2004)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
מאת: Croucher, P, et al.
יצא לאור: (2000)

Endogenous osteoprotegerin (OPG) represses ERα and promotes stemness and chemoresistance in breast cancer cells
מאת: Noura N. Alraouji, et al.
יצא לאור: (2024-08-01)

Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms
מאת: Riham Eid, et al.
יצא לאור: (2023-06-01)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
מאת: Shipman, C, et al.
יצא לאור: (2003)

Serum proinflammatory cytokines, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio in mild and severe COVID-19
מאת: Siamak Kazemi-Sufi, et al.
יצא לאור: (2024-09-01)

Human bone marrow stromal cells protect prostate and breast cancer cells from TRAIL-induced apoptosis
מאת: Nyambo, R, et al.
יצא לאור: (2004)

Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
מאת: Nyambo, R, et al.
יצא לאור: (2004)

Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats
מאת: Chan Kai-Ming, et al.
יצא לאור: (2011-07-01)

Osteoprotegerin (OPG): A potential biomarker for adverse cardiovascular events in stable coronary artery disease
מאת: Syed Muhammad Muneeb Akhtar, et al.
יצא לאור: (2024-07-01)

Osteoprotegerin and the development of myeloma bone disease
מאת: Croucher, P, et al.
יצא לאור: (2004)

Effects of osteoprotegerin from transfection of pcDNA3.1(+)/chOPG on bioactivity of chicken osteoclasts
מאת: Yao Jing, et al.
יצא לאור: (2011-03-01)

Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females
מאת: Saba Tariq, et al.
יצא לאור: (2022-02-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
מאת: Yosra Azizpour, et al.
יצא לאור: (2020-01-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
מאת: Yosra Azizpour, et al.
יצא לאור: (2020-01-01)

The survival effect of prolactin on PC3 prostate cancer cells.
מאת: Ruffion, A, et al.
יצא לאור: (2003)

Involvement of FXR in the OPG/RANKL pathway of breast and prostate cancer cells
מאת: Lara Absil, et al.
יצא לאור: (2021-04-01)

Significant Inverse Correlation of Serum Levels of Osteoprotegerin (OPG) and Transferrin Saturation in Thalassemia Dependent Transfusion (TDT) Patients
מאת: Indra Wijaya, et al.
יצא לאור: (2024-01-01)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
מאת: Croucher, P, et al.
יצא לאור: (2003)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
מאת: Croucher, P, et al.
יצא לאור: (2001)

Determinant Factors and Added Value of Osteoprotegerin (OPG) to Detect Carotid Intima-Media Thickness (CIMT) in Type 2 Diabetes Mellitus Patient
מאת: Shirly Elisa Tedjasaputra, et al.
יצא לאור: (2018-06-01)

Duchenne muscular dystrophy: RANK/RANKL/OPG (receptor activator of nuclear factor-kB/RANK ligand/osteoprotegerin) system and glucocorticoids
מאת: Salvador Atilano-Miguel, et al.
יצא לאור: (2022-01-01)

Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis
מאת: Lane Denis, et al.
יצא לאור: (2012-11-01)

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
מאת: Martin Widschwendter, et al.
יצא לאור: (2015-10-01)

Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells
מאת: Cross, N, et al.
יצא לאור: (2008)

Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells.
מאת: Cross, N, et al.
יצא לאור: (2008)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
מאת: Vanderkerken, K, et al.
יצא לאור: (2003)